Thibault Helleputte
CEO & co-founder
DNALYTICS
Louvain-La-Neuve, Belgium
11 profile visitsSpeaker
My organisation
DNAlytics brings cutting-edge data sciences expertise tailored to the healthcare sector, with a particular focus on driving innovation in advanced therapies and biomanufacturing. Founded in 2012 as a university spin-off by Prof. Pierre Dupont and Dr. Thibault Helleputte, the Belgian SME has rapidly grown into a trusted partner for over 100 collaborations spanning biotech, pharma, medtech, academic institutions, and hospitals. With extensive experience supporting the development of Advanced Therapy Medicinal Products (ATMPs), DNAlytics understands the unique challenges of the biomanufacturing landscape, from optimizing bioprocesses to ensuring data interoperability. The company has a proven track record of translating complex healthcare data into actionable insights that accelerate product development, streamline production, and enhance regulatory compliance. DNAlytics’ innovative work is backed by over 50 scientific publications and a portfolio of proprietary and open-source software, downloaded nearly 450,000 times globally. This expertise has been recognized by industry giants like IBM, Microsoft, and MIT, as well as the European Commission, underscoring DNAlytics’ position as a leader in the digital transformation of healthcare and biomanufacturing. For biomanufacturers developing ATMPs, DNAlytics offers a unique value proposition: a deep understanding of data science, regulatory compliance, and the specific demands of ATMP development, making it an ideal partner for driving forward innovation and efficiency in this rapidly growing field.
Speaker sessions (1)
Tuesday, 23 September 2025
13:30 - 14:15
Interactive panel - Building a Belgian Vaccine Trial Network
Location:SurréalisteTrack:Satellite session
Can Belgium lead in vaccine research again? This talk shares a bold plan to build a national trial network, starting in Wallonia, to boost jobs, strengthen health readiness, and bring Belgium back to the forefront of global vaccine R&D.